IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of IRIX opened at $1.85 on Tuesday. IRIDEX has a twelve month low of $1.27 and a twelve month high of $3.65. The firm’s fifty day simple moving average is $1.64 and its 200-day simple moving average is $1.92. The firm has a market capitalization of $30.78 million, a price-to-earnings ratio of -2.76 and a beta of 0.81. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The company had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same quarter last year, the business earned ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.